Regulus Therapeutics (RGLS) Misses Q3 EPS by 4c

Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.21), $0.04 worse than the analyst estimate of ($0.17).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
• Alta Mesa Resources (AMR) Misses Q2 EPS by 128c
• PFE builds bull case at $26 after earnings beat and insider buys